Artificial Intelligence-assissted Glaucoma Evaluation

NCT ID: NCT03268031

Last Updated: 2020-10-22

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

10800 participants

Study Classification

OBSERVATIONAL

Study Start Date

2017-08-15

Study Completion Date

2020-02-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Glaucoma is currently the second leading cause of irreversible blindness in the world. Our study intends to combine clinical data of glaucoma patients in Zhongshan Ophthalmic Center with Artificial Intelligence techniques to create programs that can screen and diagnose glaucoma.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Glaucoma is currently the second leading cause of irreversible blindness in the world, which brings heavy burden to human society. Compared to other ocular diseases, diagnostic process of glaucoma is complicated depends on multiple test results, including visual field test, OCT, etc. How to diagnose glaucoma correctly and fast has always been a hot topic in glaucoma researches. Artificial intelligence is used to study and develop theories and methods that can help simulate and extend human intelligence, which has been utilized in a lot of research fields such as automatic drive and medicine. The study intends to combine clinical data of glaucoma patients in Zhongshan Ophthalmic Center with Artificial Intelligence techniques to create programs that can screen and diagnose glaucoma.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Artificial Intelligence Glaucoma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Glaucoma patients

Glaucoma patients will take visual field test and OCT imaging of optic nerve area. All of these data will be collected as source of machine learning.

Visual field and OCT tests

Intervention Type DIAGNOSTIC_TEST

Visual field test and OCT are commonly used essential tests to make accurate diagnosis of glaucoma. Algorithms to classify Visual field and OCT tests would both be developed and verified.

Non-glaucoma participants

Non-glaucoma participants will take visual field test and OCT imaging of optic nerve area. All of these data will be collected as source of machine learning.

Visual field and OCT tests

Intervention Type DIAGNOSTIC_TEST

Visual field test and OCT are commonly used essential tests to make accurate diagnosis of glaucoma. Algorithms to classify Visual field and OCT tests would both be developed and verified.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Visual field and OCT tests

Visual field test and OCT are commonly used essential tests to make accurate diagnosis of glaucoma. Algorithms to classify Visual field and OCT tests would both be developed and verified.

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. BCVA\>0.1
2. able to complete reliable visual field test
3. no history of intraocular surgery or fundus laser

Exclusion Criteria

1\. unable to complete visual field test
Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Chinese Academy of Sciences

OTHER_GOV

Sponsor Role collaborator

Sun Yat-sen University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Xiulan Zhang

Director of Clinical Research Center

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Xiulan Zhang, Doctor

Role: PRINCIPAL_INVESTIGATOR

Sun Yat-sen University

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Zhongshan Ophthalmic Center

Guangzhou, Guangdong, China

Site Status

Countries

Review the countries where the study has at least one active or historical site.

China

References

Explore related publications, articles, or registry entries linked to this study.

Diprose W, Buist N. Artificial intelligence in medicine: humans need not apply? N Z Med J. 2016 May 6;129(1434):73-6.

Reference Type RESULT
PMID: 27349266 (View on PubMed)

Quigley HA. Glaucoma. Lancet. 2011 Apr 16;377(9774):1367-77. doi: 10.1016/S0140-6736(10)61423-7. Epub 2011 Mar 30.

Reference Type RESULT
PMID: 21453963 (View on PubMed)

Asaoka R, Murata H, Iwase A, Araie M. Detecting Preperimetric Glaucoma with Standard Automated Perimetry Using a Deep Learning Classifier. Ophthalmology. 2016 Sep;123(9):1974-80. doi: 10.1016/j.ophtha.2016.05.029. Epub 2016 Jul 7.

Reference Type RESULT
PMID: 27395766 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

ProjectAGE

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.